The purpose of BuZonE RCT (randomized-controlled trial) is to see if taking a combination of zonisamide and bupropion for a short time helps you switch to using only an e-cigarette.
A maximum of 180 adult male and female cigarette smokers, aged 21-65 years, will be enrolled from Raleigh and Charlotte, North Carolina, and surrounding areas.
Zonisamide is a drug approved by the United States Food and Drug Administration (FDA) for treatment of seizures. Bupropion (also known as Zyban) is a drug approved by the FDA for use as an aid to quit smoking (but not for switching from combustible cigarettes to e-cigarettes). The use of the combination of zonisamide and bupropion is not FDA approved for the purpose of switching from combustible cigarettes to e-cigarette use and is therefore considered investigational for this study.
You will be compensated for the time related to your participation in this study. Your participation in this study will last 13-14 weeks and will include 7 visits to the study center.